169 related articles for article (PubMed ID: 11953862)
1. Role of proteolytic enzymes in human prostate bone metastasis formation: in vivo and in vitro studies.
Hart CA; Scott LJ; Bagley S; Bryden AA; Clarke NW; Lang SH
Br J Cancer; 2002 Apr; 86(7):1136-42. PubMed ID: 11953862
[TBL] [Abstract][Full Text] [Related]
2. Interaction of prostate epithelial cells from benign and malignant tumor tissue with bone-marrow stroma.
Lang SH; Clarke NW; George NJ; Allen TD; Testa NG
Prostate; 1998 Feb; 34(3):203-13. PubMed ID: 9492849
[TBL] [Abstract][Full Text] [Related]
3. Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases.
Koutsilieris M; Frenette G; Lazure C; Lehoux JG; Govindan MV; Polychronakos C
Anticancer Res; 1993; 13(2):481-6. PubMed ID: 7685989
[TBL] [Abstract][Full Text] [Related]
4. Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator.
Shi C; Zhang N; Feng Y; Cao J; Chen X; Liu B
Cell Physiol Biochem; 2017; 41(4):1313-1324. PubMed ID: 28278500
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.
Kirchheimer JC; Pflüger H; Ritschl P; Hienert G; Binder BR
Invasion Metastasis; 1985; 5(6):344-55. PubMed ID: 4066206
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behavior in vivo.
Quax PH; de Bart AC; Schalken JA; Verheijen JH
Prostate; 1997 Aug; 32(3):196-204. PubMed ID: 9254899
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid.
Webber MM; Waghray A
Clin Cancer Res; 1995 Jul; 1(7):755-61. PubMed ID: 9816042
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma.
Festuccia C; Vincentini C; di Pasquale AB; Aceto G; Zazzeroni F; Miano L; Bologna M
Oncol Res; 1995; 7(3-4):131-8. PubMed ID: 8555646
[TBL] [Abstract][Full Text] [Related]
9. Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion.
Festuccia C; Giunciuglio D; Guerra F; Villanova I; Angelucci A; Manduca P; Teti A; Albini A; Bologna M
Oncol Res; 1999; 11(1):17-31. PubMed ID: 10451028
[TBL] [Abstract][Full Text] [Related]
10. Increased levels of urokinase plasminogen activator receptor in prostate cancer cells derived from repeated metastasis.
Forbes K; Gillette K; Kelley LA; Sehgal I
World J Urol; 2004 Apr; 22(1):67-71. PubMed ID: 15052500
[TBL] [Abstract][Full Text] [Related]
11. Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
Waghray A; Webber MM
Clin Cancer Res; 1995 Jul; 1(7):747-53. PubMed ID: 9816041
[TBL] [Abstract][Full Text] [Related]
12. Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.
Leto G; Badalamenti G; Arcara C; Crescimanno M; Flandina C; Tumminello FM; Incorvaia L; Gebbia N; Fulfaro F
Anticancer Res; 2006; 26(1A):23-6. PubMed ID: 16475674
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of expression of urokinase-type plasminogen activator in patients with prostate cancer.
Ohta S; Fuse H; Fujiuchi Y; Nagakawa O; Furuya Y
Anticancer Res; 2003; 23(3C):2945-50. PubMed ID: 12926141
[TBL] [Abstract][Full Text] [Related]
14. Human prostate tumor angiogenesis in nude mice: metalloprotease and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells.
Wilson MJ; Sinha AA
Anat Rec; 1997 Sep; 249(1):63-73. PubMed ID: 9294650
[TBL] [Abstract][Full Text] [Related]
15. Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells.
Festuccia C; Angelucci A; Gravina GL; Villanova I; Teti A; Albini A; Bologna M
Int J Cancer; 2000 Feb; 85(3):407-15. PubMed ID: 10652434
[TBL] [Abstract][Full Text] [Related]
16. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
17. Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis.
Ports MO; Nagle RB; Pond GD; Cress AE
Cancer Res; 2009 Jun; 69(12):5007-14. PubMed ID: 19491258
[TBL] [Abstract][Full Text] [Related]
18. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
19. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
[TBL] [Abstract][Full Text] [Related]
20. Gene transfer of the urokinase-type plasminogen activator receptor-targeted matrix metalloproteinase inhibitor TIMP-1.ATF suppresses neointima formation more efficiently than tissue inhibitor of metalloproteinase-1.
Lamfers ML; Grimbergen JM; Aalders MC; Havenga MJ; de Vries MR; Huisman LG; van Hinsbergh VW; Quax PH
Circ Res; 2002 Nov; 91(10):945-52. PubMed ID: 12433840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
